APRN Practice Exam 2025 – Full ANCC Exam Prep Resource

Sertraline, a selective serotonin reuptake inhibitor (SSRI) commonly prescribed for conditions such as depression and anxiety, is associated with an increased risk of suicidal ideation, particularly in younger populations. The mechanism is believed to be related to the initial activation of the serotonin system in the brain, which can lead to increased feelings of agitation or anxiety before the beneficial effects of the medication take hold.

Monitoring for suicidal thoughts or behaviors is a critical component of management for any patient beginning treatment with SSRIs, as the risk is particularly prominent in the early stages of treatment or when there are adjustments in dosage. This makes vigilant assessment for any signs of worsening mood or emerging suicidal thoughts essential for patient safety.

In contrast, while weight gain, gastrointestinal bleeding, and mood swings can occur in patients taking sertraline, they do not present the immediate life-threatening risk that necessitates urgent evaluation and intervention. Weight gain can be more long-term and variable among individuals, gastrointestinal bleeding is a less common concern typically associated with NSAIDs rather than SSRIs, and while mood swings can be a symptom of underlying conditions, they are not specifically indicative of the acute risk pattern that suicidal ideation presents.